Q3 EPS Estimates for Kura Oncology Cut by Leerink Partnrs

Kura Oncology, Inc. (NASDAQ:KURA) – Leerink Partnrs lowered their Q3 2025 EPS estimates for Kura Oncology in a research report issued on Wednesday, May 14th. Leerink Partnrs analyst J. Chang now anticipates that the company will earn $0.15 per share for the quarter, down from their previous forecast of $0.16. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Leerink Partnrs also issued estimates for Kura Oncology’s Q4 2025 earnings at $0.18 EPS, FY2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.69) EPS.

A number of other equities research analysts have also recently issued reports on KURA. Wedbush reissued an “outperform” rating and issued a $36.00 price target on shares of Kura Oncology in a research note on Tuesday, April 8th. JMP Securities reiterated a “market outperform” rating and issued a $28.00 price objective on shares of Kura Oncology in a report on Tuesday, April 29th. BTIG Research cut Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. UBS Group lowered their price target on Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. Finally, Cantor Fitzgerald upgraded Kura Oncology to a “strong-buy” rating in a report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $24.50.

Kura Oncology Stock Up 2.2%

KURA opened at $6.38 on Monday. The company has a fifty day moving average of $6.37 and a two-hundred day moving average of $8.63. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a fifty-two week low of $5.41 and a fifty-two week high of $23.48. The stock has a market capitalization of $552.35 million, a price-to-earnings ratio of -2.70 and a beta of 0.50.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.15). The firm had revenue of $14.11 million for the quarter, compared to analysts’ expectations of $39.08 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of KURA. Barclays PLC boosted its position in Kura Oncology by 104.5% in the 3rd quarter. Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after buying an additional 84,563 shares during the last quarter. SG Americas Securities LLC purchased a new position in Kura Oncology in the fourth quarter valued at about $436,000. Moody Aldrich Partners LLC boosted its holdings in Kura Oncology by 42.3% in the fourth quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock valued at $1,251,000 after purchasing an additional 42,712 shares during the last quarter. Jennison Associates LLC acquired a new stake in Kura Oncology during the 4th quarter valued at approximately $623,000. Finally, Virtu Financial LLC purchased a new stake in Kura Oncology during the 4th quarter worth approximately $139,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.